The 2013 updated American Society of Clinical Oncology/College of American Pathologists (ASCO/ CAP) guidelines on human epidermal growth factor receptor 2 (HER2) testing in breast cancer described different groups of HER2 positive in situ hybridization (ISH) results based on both the HER2/centromere ratio and the average HER2 copy number per cell ❚Table 1❚.
The 2013 updated American Society of Clinical Oncology/College of American Pathologists (ASCO/ CAP) guidelines on human epidermal growth factor receptor 2 (HER2) testing in breast cancer described different groups of HER2 positive in situ hybridization (ISH) results based on both the HER2/centromere ratio and the average HER2 copy number per cell ❚Table 1❚. 1, 2 Certain subcategories of breast cancers defined by ISH as "HER2 amplified" have been controversial due to the fact that the ratio and copy number yield conflicting information with regard to HER2 amplification status. 3, 4 One category is group 2 breast cancers with a positive ratio but low HER2 copy number (<four average copies per cell); patients with ISH results in this category were historically qualified for targeted therapy due to a positive HER2/ centromere ratio, but responsiveness to targeted therapy has not been sufficiently demonstrated for this subgroup. Another category is Group 3 breast cancers with elevated HER2 copy number (average HER2 copy number ≥6.0) but a negative ratio. A third area of controversy in HER2 testing is the resolution of clinical HER2 status in breast cancers that are equivocal by both immunohistochemistry (IHC) and ISH. Although US Food and Drug Administration (FDA)-approved clinical ISH tests did not include an equivocal range for result reporting, both the 2007 and 2013 ASCO/CAP ISH guidelines defined an equivocal range; in the former (2007) guideline, equivocal status was defined by a HER2/centromere ratio between 1.8 and 2.2 for dual-probe assays or a HER2 copy number between 4.0 and 5.9 for single-probe assays, 5, 6 and in the latter (2013) guideline, equivocal was redefined as an average HER2 copy number per cell between 4.0 and 5.9 for single-or dual-probe assays, along with a HER2/centromere ratio less than 2.0 for dual-probe assays (group 4). 1, 2 In addition to group 2, group 3, and group 4 ISH results, a fourth category of nonclassical ISH results is genetic heterogeneity with HER2 amplified and nonamplified populations of tumor cells. 7 Nonclassical ISH patterns present diagnostic challenges for the laboratory and have generated uncertainty over the best clinical management of these cancers.
Additional data are needed to determine what subgroups of HER2 ISH results, aside from those with both high HER2 copy number and high HER2/centromere ratio, are potentially responsive to targeted therapy; in the interim, follow-up testing is desirable for those cases that do not generate a classic positive (group 1) or negative (group 5) result by standard ISH assays and show equivocal (2+) IHC results. For cases where HER2 amplification status is unclear or unresolved by ISH, cytogenomic microarray (CMA) can be a useful adjunctive test to refine HER2 copy number analysis. In this study, we performed CMA on four cases with nonclassical ISH results and correlated the CMA data with pathologic review and reverification of the ISH results.
Materials and Methods
Cases were selected from clinical residual material remaining after clinical testing was completed. Fluorescence in situ hybridization (FISH), a commonly used ISH method, was performed with the PathVysion dual-probe assay (Abbott Molecular, Des Plaines, IL) using a laboratory-validated procedure as described previously. 3 Two reviewing pathologists (K.B.G. and B.C.) independently evaluated each case for invasive and in situ tumor content and estimated the percentage of tumor nuclei (tumor cellularity) based on microscopic review of H&E-stained sections. Area(s) of invasive tumor with 5% or less in situ tumor content were manually circled on the H&E slides. For CMA, manual macrodissection was performed on five to 10 unstained sections, guided by the pathologist's circled area(s) on an adjacent H&E-stained section. DNA extraction and sample processing was performed according to manufacturer instructions, and the DNA samples were run on the OncoScan CMA platform (ThermoFisher Scientific, Waltham, MA) as described previously. 8 The OncoScan platform contains single nucleotide polymorphism (SNP) probes to allow genome-wide analysis of both copy number and allelic states, including copy neutral loss of heterozygosity (LOH). Arrays were analyzed using the TuScan segmentation algorithm in Chromosome Analysis Suite software (ChAS version 3.1, ThermoFisher Scientific) and the SNP-FASST2 segmentation algorithm in Nexus Express Software for OncoScan (version 3.1, BioDiscovery, El Segundo, CA), with copy number calling thresholds set at 50 markers or more for gains and 25 markers or more for losses. The TuScan segmentation algorithm generates an integer copy number state, inferred ploidy level, and percentage of abnormal cells in mode 1, and if the algorithm cannot resolve the ploidy and percentage of abnormal cells, the algorithm defaults to mode 2. Arrays were manually reviewed and recentered if integrated review of the CMA and ISH data indicated that recentering was appropriate. Chromosome 17 was then specifically examined for the presence of copy number abnormalities around the HER2 gene region and pericentromeric regions (p arm and q arm regions flanking the centromere of chromosome 17). Copy number by ISH was correlated with the median log 2 ratios for segments overlapping the region of interest using the equations shown in ❚Figure 1❚. The pathologists' estimated tumor content was used for the tumor cellularity. Ploidy was initially assumed to be diploid (N = 2) for correlating ISH data with the HER2 copy number by array, and for those cases with abnormal ploidy designated by the TuScan algorithm, a value of 2 was used for N in order to correlate the 
Case 1
A 57-year-old woman with a history of metastatic breast cancer was admitted to the emergency department of a regional hospital with progressive aphasia. Computed tomography scanning identified a mass in the left cerebral cortex. A biopsy was performed, and the pathologic diagnosis was metastatic carcinoma consistent with a breast primary. Estrogen receptor (ER) IHC was negative (0% nuclear staining), but progesterone receptor (PR) IHC was positive, with approximately 80% of the tumor nuclei showing weak staining. HER2 IHC was equivocal (2+). ISH showed a positive result according to 2013 ASCO/ CAP guidelines (group 2), with HER2 copy number of 2.1 and HER2/centromere ratio of 2.1; the average copy number for the centromere probe (D17Z1) was 1.0 copy per cell (Image 1A, Table 2 ). CMA was performed on a manually macrodissected area of the biopsy specimen; the pathologist estimated tumor cellularity was 90%. According to the TuScan segmentation algorithm, the tumor is diploid, and visual review of the data confirms several regions with balanced alleles that are appropriately positioned at the baseline (including 6p22.1-6q25.1 and all of chromosome 19) ( Figure 2 ). The allele information provided by CMA indicates LOH for over half of the genome, including all of chromosome 17 ( Figure 2 ).
❚Figure 1❚ Simplified mathematical description of the log 2 ratio designation of copy number state on genomic platforms, applied to samples containing a mixture of tumor and nontumor DNA. A, The theoretical log 2 ratio can be described as a ratio of the copy number of the genomic region of interest (numerator) to the baseline genomic copy number state (denominator). In the formula, X = copy number for the segment of interest, CF = tumor cellularity (proportion of cell nuclei that are tumor), and N = ploidy level of the tumor (normal ploidy = 2, diploid). This formula applies to samples in which the tumor is genetically homogeneous with respect to the genomic region of interest and the baseline genomic copy number state. B, For samples with more than one abnormal tumor cell population, the left half of the equation must be broken into components (population 1, 2, 3…). C, The actual log 2 ratio observed on a specific genomic platform deviates from the theoretical log 2 ratio in a systematic way within the linear range and can be correlated with the theoretical log 2 ratio by using a platform-specific correction factor (ρ).
There is a loss on 17p that overlaps the centromere and includes proximal 17q; HER2 is within a normal copy number region on 17q, correlating with the average copy number per cell obtained by ISH (2.1 average copies per cell). There is no evidence of HER2 amplification; however, there is a spike in the log 2 plot with LOH in a 765-kilobase pair segment on 7q22.1 containing HGF (hepatocyte growth factor) and CDK6. The widespread LOH in this case suggests endoreduplication of a hypodiploid genome, and there is evidence of chromothripsis as well (eg, chromosome 11), suggesting that a single catastrophic event may have caused multiple chromosomal breaks and losses. 9 In summary, the combined evidence from ISH and CMA shows no evidence of HER2 amplification, but there is evidence of possible amplification of 7q22.1, including HGF and CDK6. In addition to ❚Image 1❚ Nonclassical patterns of copy number aberration for HER2 (red signals) and CEP17 (green signals) observed by fluorescence in situ hybridization (FISH). A, Case 1. Low HER2 copy number with a positive HER2/centromere ratio as a consequence of loss of the centromere (monosomy) (Group 2). Despite an average HER2 copy number of only 2.1, the HER2/centromere ratio is 2.1; this is a consequence of copy number loss affecting the centromere (copy number = 1.0). B, Case 2. HER2 average copy number ≥6 with a negative HER2/centromere ratio. The average HER2 copy number is 6.5 and the HER2/centromere ratio is 1.2 (group 3). C, Case 3. 2013 American Society of Clinical Oncology/College of American Pathologists category of equivocal FISH results with an average HER2 copy number between 4 and 5.9 copies per cell and a negative HER2/centromere ratio. The HER2 copy number in this sample is 4.1 and the ratio is 1.2 (group 4). D, Reflex FISH testing (same sample shown in C) with a HER2 probe (red) and an alternate control probe, D17S122 (green), yields an amplified ratio of 2.1.
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AJCP / Original article providing information about additional potential therapeutic targets, the CMA results could help support a clinical decision to avoid HER2-targeted therapy.
Case 2
A 64-year-old woman had a core biopsy performed on a suspicious lesion of the left breast detected by mammography. The pathologic diagnosis on the core biopsy was atypical ductal hyperplasia. The excision (lumpectomy) specimen showed high-grade invasive ductal carcinoma: 1.2 cm in greatest dimension. ER and PR expression by IHC were negative, and HER2 IHC was equivocal (2+). ISH showed a positive result according to 2013 ASCO/CAP guidelines (group 3), with HER2 copy number of 6.5 and HER2/centromere ratio of 1.2 (Image 1B, Table 2 ). CMA was performed on a manually macrodissected area of the 
was 60% to 70%. Ploidy level was not indicated by the TuScan segmentation algorithm. However, the log 2 plot appears to be centered appropriately on several regions of lowest copy number state with balanced alleles (5p13-qter, 9q, 15q15.1-q26.1), and the presence of multiple gains across the genome is consistent with hyperdiploidy ( Figure 3 
with 60% to 70% tumor cellularity; however, the average HER2 copy number observed by ISH is 6.5 copies per cell. After reconfirming approximately 60% to 70% tumor cellularity on the H&E slide and reconfirming the HER2 copy number by review of the ISH slide, this discrepancy between HER2 copy number by ISH and HER2 copy number by CMA indicates that the baseline of the array is not diploid. Using the equation shown in Figure 1 with HER2 copy number (X) equal to 6.5 and a platform-specific correction factor (ρ) equal to 0.8, the calculated ploidy level (N) in a 60% to 70% tumor sample is between 4.5 and 4.6. Reinterpreting the baseline on the CMA log 2 plot as copy number equal to 4, the additional copy gain encompassing 17p11.2-qter (including the centromere and HER2) is consistent with the ISH results, and the gains of multiple other regions of the genome are consistent with a ploidy level greater than 4. The CMA result can therefore be interpreted as hyperdiploid (or hypertetraploid), with an additional low-level gain of 17p11.2-qter but no evidence of HER2 amplification. If this breast cancer were to be reclassified as ER, PR, and HER2 negative rather than HER2 positive, the treatment approach might change, and depending on the patient's family history, genetic testing for an inherited cancer gene mutation (including BRCA1/BRCA2) might be indicated.
Case 3
A 53-year-old woman had core biopsies performed on a suspicious lesion with calcifications detected by mammography. The pathologic diagnosis was invasive ductal carcinoma, grade 3 (0.7 cm in greatest dimension). ER and PR IHC results were positive (95% strong nuclear staining for ER and 75% moderate-to-strong nuclear staining for PR). The HER2 IHC result was equivocal (2+ Per the laboratory's protocol for an equivocal HER2 ISH result using the standard FDA-approved ISH assay, reflex testing was performed using a differentially labeled probe set containing an alternate control probe (D17S122) and a probe targeting the HER2 gene, and the HER2/D17S122 ratio was positive (ratio = 2.1); therefore, a positive HER2 result was reported (Image 1D). CMA was performed on a manually macrodissected area of the biopsy specimen containing invasive tumor and no in situ tumor; the initial pathologist estimated tumor cellularity was 80% to 90%. The CMA result shows a high degree of genomic complexity ( Figure 4 ). According to the TuScan segmentation algorithm, the ploidy level is 4, and there is a segmental gain overlapping HER2 corresponding to HER2 copy number between 2.9 and 3.0, using the equation shown in Figure 1 HER2 copies per cell). However, careful reevaluation of the tumor cellularity was performed by a breast pathologist upon integrated review of the data, and the tumor cellularity was estimated to be closer to 60% to 80% (Table 2) . After confirming the average HER2 copy number of approx- control ratio was observed in the reflex ISH assay using the D17S122 control probe, since there is loss of that region (17p12) relative to the HER2 gene region on 17q12. In this case, given the small size of the tumor (provided the patient has no metastatic disease), the cancer might be adequately treated with endocrine therapy. Gene expression studies (eg, Oncotype DX or Prosigna) could also be helpful in determining the best treatment options for this patient. Avoiding HER2-targeted therapy could reduce the overall cost of care and potential for cardiotoxicity in this patient.
Case 4
A 37-year-old woman had a core biopsy performed on a suspicious lesion of the left breast detected by mammography. A suspicious mass in the left axilla was also biopsied and found to contain metastatic carcinoma. The greater than 20 (signals too numerous to count) and the remaining 85% of cells showing an average HER2 copy number of 2.0 (Image 2). The biopsy material from the left axilla showed a negative result (average HER2 copies per cell = 1.9, HER2/centromere ratio = 1.1). CMA was performed on a manually macrodissected area of the left breast core biopsy specimen containing invasive tumor and no in situ tumor; the pathologist estimated tumor cellularity was 80% to 90%. According to the TuScan segmentation algorithm, the ploidy level is 3, and visual review of the data shows a genome with apparent triploidy (four allele states-AAA, AAB, ABB, and BBB-in the majority of the genome), with several diploid appearing regions (balanced A and B alleles with three allele states-AA, AB, and BB) where the log 2 plots are appropriately positioned at the baseline (4q31.23-q34.3, 5q13.3-q35.1, Xpter-p21.1) (Figure 6 ). An amplicon overlapping HER2 is easily identified, along with several other amplified regions on 2q and 13q, without cancer genes of interest. The median log 2 ratio for the amplicon overlapping HER2 corresponds to an average copy number of 6.6 to 7.2 in an 80% to 90% homogeneous tumor sample, according to the equation in Figure 1 . However, the tumor is known to be heterogeneous for HER2 amplification by IHC and ISH, and the chromosome 17 centromere probe results for the two populations also suggest different ploidy states within the tumor. The equation shown in Figure 1 can be used to solve for HER2 copy number in a heterogeneous population; the derived HER2 copy number in the amplified population (15% of the tumor) is approximately 32.8. ISH copy number in this case was above the range where individual signals could be accurately enumerated; the true HER2 copy number is probably between 30 and 40 copies per cell. In summary, the HER2 amplification detected by ISH in this patient's tumor biopsy was identifiable by CMA; however, correlation with the ISH data was required to accurately assess the CMA data.
Discussion
Our study shows the power of integrated copy number analysis using ISH and CMA. Because ISH is ideally suited for determining the copy number per cell, and the copy number of the invasive tumor can be specifically interrogated by this method, the data on the copy number obtained by ISH can be used to guide the interpretation of the CMA results. Conversely, whereas ISH may inaccurately assign HER2 amplification status due to aforementioned issues with the ratio, as well as other preanalytic and analytic factors affecting ISH testing, CMA can support accurate interpretation of ISH copy number by providing an overall landscape of the copy number changes in the tumor sample tested. Chromosome 17 copy number changes are frequent in breast cancer, and copy number changes affecting the control probe region can skew the HER2/control ratio. Instead of relying upon a single control probe, CMA provides data at a much higher resolution for HER2 copy number relative to the rest of the genome. SNP-based array platforms such as those used in this study also permit characterization of allelic imbalances, and therefore SNP arrays are preferred for CMA analysis of neoplastic disorders.
10 Case 1 provides an interesting example of widespread LOH that can occur in endoreduplication of a genome with numerous chromosomal losses; this LOH would not have been detected in a copy number only CMA platform, highlighting the advantage of SNP-based CMA analysis.
CMA cannot characterize the same exact tumor cell population as ISH, and so integrated analysis must account for possible subclones and varying levels of nontumor content. Moreover, clonal evolution and the presence of multiple subclonal populations can complicate the interpretation of ploidy states on CMA, and as we demonstrated on this study, correlation with ISH data and pathologic review of tumor cellularity is required for accurate interpretation of CMA results on breast cancer. While the TuScan algorithm appropriately identified abnormal ploidy in two cases, the log 2 plot was not initially centered appropriately in one case (case 3) and genetic heterogeneity resulted in misrepresentation of HER2 copy number in another case (case 4).
Our study has several limitations. Pathologists' review of tumor cellularity is very subjective and known to be error prone. 11, 12 In this study, pathology review was performed very carefully; however, in one case, there was a large discrepancy between the initial estimate of tumor cellularity (80% -90%) and the follow-up estimate of tumor cellularity (60%) based on integrated review of the ISH and CMA data. In a busy clinical practice, rapid slide review can result in large errors in the estimated tumor percentage. This limitation of our study method underscores the importance of integrated review of ISH and CMA with a pathologist present to reconfirm the tumor cellularity on the slide. This study was also limited in the number of cases studied, and the genomic data we obtained cannot be generalized with regard to each category of nonclassical ISH results. Genomic analysis also requires a larger amount of sample, and contamination from in situ tumor and nontumor must be minimized; consequently, many clinical biopsy specimens may be inadequate for the type of integrated analysis performed in this study. Finally, the IHC on three of our cases (cases 1-3) was performed and interpreted at an outside laboratory, and follow-up IHC could not be performed internally.
While CMA is more expensive than IHC for follow-up testing on challenging categories of HER2 ISH results, CMA provides additional clinically useful information. As we showed in two cases, CMA can identify amplification of other potentially targetable oncogenes. CMA may also be useful for characterizing genetic subtypes of breast cancer. Certain recurrent cytogenetic abnormalities have been correlated with clinical outcomes, and recent large genomic studies have shown a more comprehensive view of these recurrent copy number changes by CMA. 13, 14 While genomic studies have demonstrated recurrent copy number changes associated with different outcomes, the clinical utility of these data remains uncertain. In the future, integrated genomic profiling of copy number and sequence data at the DNA level, along with expression profiling at the RNA level, may become a robust adjunctive test method for clarifying clinical molecular subtypes of breast cancer.
